Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07169942 · ClinicalTrials.gov registry record · Phase 2
Aleniglipron Phase 2 Body Composition Study
A Phase 2 study of Obesity, Overweight, or Chronic Weight Management, sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 71
- Enrollment target
- 11
- Study locations
NCT07169942 is a Phase 2 study of Obesity, Overweight, or Chronic Weight Management that is active but no longer recruiting, run by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. The registered enrollment target is 71 participants. The trial reports 11 study locations across 9 states.
The verdict
NCT07169942, a Phase 2 study of Obesity, Overweight, or Chronic Weight Management, is active but no longer recruiting, sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 71 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled study evaluating the effects of aleniglipron on body composition in participants living with obesity. Participants will be randomized to aleniglipron or placebo in a ratio of 5:1. Participants will receive multiple ascending QD doses of aleniglipron or placebo in titration steps of 4 weeks duration for a total of 40 weeks of treatment.
Conditions Studied
Interventions
- DRUG aleniglipron or placebo
Study Locations (11)
South Carolina
- Research Site - Moncks Corner
- Research Site - North Charleston
Texas
- Research Site - Austin
- Research Site - San Antonio
Arizona
- Research Site - Phoenix
Illinois
- Research Site - Chicago
Minnesota
- Research Site - Richfield
Missouri
- Research Site - City of Saint Peters
New York
- Research Site - Rochester
North Carolina
- Research Site - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2025-08-15 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07169942
The ClinicalTrials.gov registry entry for NCT07169942 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity, Overweight, or Chronic Weight Management appearing as the primary indexed condition, and to 1 intervention - of which aleniglipron or placebo is the first listed.
NCT07169942 reports 11 study locations spanning 9 distinct geographic areas - top geographies include South Carolina, Texas, Arizona.
Frequently Asked Questions
What is clinical trial NCT07169942 about?
NCT07169942 is a clinical study titled "Aleniglipron Phase 2 Body Composition Study". This is a randomized, double-blind, placebo-controlled study evaluating the effects of aleniglipron on body composition in participants living with obesity. Participants will be randomized to aleniglipron or placebo in a ratio of 5:1. Participants will receive multiple ascending QD doses of alenigli...
What is the current status of trial NCT07169942?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 71 participants. The study started on 2025-08-15. Estimated completion is 2026-10.
What conditions does trial NCT07169942 study?
This clinical trial studies the following conditions: Obesity, Overweight, or Chronic Weight Management.
What interventions are being tested in trial NCT07169942?
The interventions under investigation include: aleniglipron or placebo (DRUG).
Who is sponsoring clinical trial NCT07169942?
This trial is sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07169942 being conducted?
This trial has 11 study locations across Arizona, Illinois, Minnesota, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity, Overweight, or Chronic Weight Management
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.